Reshaping the Tumour Immune Microenvironment in Solid Tumours Via Tumour Cell and Immune Cell DNA Methylation: from Mechanisms to Therapeutics

Overview

Journal Br J Cancer

Specialty Oncology

Date 2023 Apr 28

PMID 37117649

Authors

Fengyun Zhong

Yilin Lin

Long Zhao

Changjiang Yang

Yingjiang Ye

Zhanlong Shen

Affiliations

Soon will be listed here.

Abstract

In recent years, the tumour microenvironment (TME) of solid tumours has attracted more and more attention from researchers, especially those non-tumour components such as immune cells. Infiltration of various immune cells causes tumour immune microenvironment (TIME) heterogeneity, and results in different therapeutic effects. Accumulating evidence showed that DNA methylation plays a crucial role in remodelling TIME and is associated with the response towards immune checkpoint inhibitors (ICIs). During carcinogenesis, DNA methylation profoundly changes, specifically, there is a global loss of DNA methylation and increased DNA methylation at the promoters of suppressor genes. Immune cell differentiation is disturbed, and exclusion of immune cells from the TME occurs at least in part due to DNA methylation reprogramming. Therefore, pharmaceutical interventions targeting DNA methylation are promising. DNA methyltransferase inhibitors (DNMTis) enhance antitumor immunity by inducing transcription of transposable elements and consequent viral mimicry. DNMTis upregulate the expression of tumour antigens, mediate immune cells recruitment and reactivate exhausted immune cells. In preclinical studies, DNMTis have shown synergistic effect when combined with immunotherapies, suggesting new strategies to treat refractory solid tumours.

Citing Articles

Aberrant DNA methylation as a key modulator of cell death pathways: insights into cancer progression and other diseases.

Zahoor A, Khazer R, Mehraj I, Gani U, Fayaz F, Khanday F Funct Integr Genomics. 2025; 25(1):50.

PMID: 40024973 DOI: 10.1007/s10142-025-01552-x.

CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches.

Kwantwi L, Boafo J, Egleh B, Li M Clin Transl Oncol. 2025; .

PMID: 39985603 DOI: 10.1007/s12094-025-03874-5.

DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy.

Lofiego M, Tufano R, Bello E, Solmonese L, Marzani F, Piazzini F J Exp Clin Cancer Res. 2025; 44(1):58.

PMID: 39966970 PMC: 11834541. DOI: 10.1186/s13046-025-03310-0.

Exploring viral mimicry combined with epigenetics and tumor immunity: new perspectives in cancer therapy.

Wang R, Dong X, Zhang X, Liao J, Cui W, Li W Int J Biol Sci. 2025; 21(3):958-973.

PMID: 39897033 PMC: 11781167. DOI: 10.7150/ijbs.103877.

Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment.

Zheng L, Chang R, Liang B, Wang Y, Zhu Y, Jia Z Cancer Drug Resist. 2025; 7():50.

PMID: 39802949 PMC: 11724354. DOI: 10.20517/cdr.2024.107.

References

Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View

Joosten S, Smits K, Aarts M, Melotte V, Koch A, Tjan-Heijnen V . Epigenetics in renal cell cancer: mechanisms and clinical applications. Nat Rev Urol. 2018; 15(7):430-451. DOI: 10.1038/s41585-018-0023-z. View

Lao V, Grady W . Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011; 8(12):686-700. PMC: 3391545. DOI: 10.1038/nrgastro.2011.173. View

Garcia-Martinez L, Zhang Y, Nakata Y, Chan H, Morey L . Epigenetic mechanisms in breast cancer therapy and resistance. Nat Commun. 2021; 12(1):1786. PMC: 7979820. DOI: 10.1038/s41467-021-22024-3. View

Jingyao C, Xiangyu P, Feifei N, Xuelan C, Chong C . Epigenetic reprogramming in small cell lung cancer. Cancer Biol Med. 2022; 19(8). PMC: 9425178. DOI: 10.20892/j.issn.2095-3941.2022.0343. View

Mehta A, Dobersch S, Romero-Olmedo A, Barreto G . Epigenetics in lung cancer diagnosis and therapy. Cancer Metastasis Rev. 2015; 34(2):229-41. DOI: 10.1007/s10555-015-9563-3. View

van der Pol Y, Mouliere F . Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. Cancer Cell. 2019; 36(4):350-368. DOI: 10.1016/j.ccell.2019.09.003. View

Bates S . Epigenetic Therapies for Cancer. N Engl J Med. 2020; 383(7):650-663. DOI: 10.1056/NEJMra1805035. View

Hogg S, Beavis P, Dawson M, Johnstone R . Targeting the epigenetic regulation of antitumour immunity. Nat Rev Drug Discov. 2020; 19(11):776-800. DOI: 10.1038/s41573-020-0077-5. View

10.

Jones P, Ohtani H, Chakravarthy A, De Carvalho D . Epigenetic therapy in immune-oncology. Nat Rev Cancer. 2019; 19(3):151-161. DOI: 10.1038/s41568-019-0109-9. View

11.

Xuan L, Liu Q . Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021; 14(1):4. PMC: 7786934. DOI: 10.1186/s13045-020-01017-7. View

12.

Ren X, Zhang L, Zhang Y, Li Z, Siemers N, Zhang Z . Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment. Annu Rev Immunol. 2021; 39:583-609. DOI: 10.1146/annurev-immunol-110519-071134. View

13.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

14.

Kang Y, Boku N, Satoh T, Ryu M, Chao Y, Kato K . Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10111):2461-2471. DOI: 10.1016/S0140-6736(17)31827-5. View

15.

Cortes J, Cescon D, Rugo H, Nowecki Z, Im S, Yusof M . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265):1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. View

16.

Shitara K, Ozguroglu M, Bang Y, Di Bartolomeo M, Mandala M, Ryu M . Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018; 392(10142):123-133. DOI: 10.1016/S0140-6736(18)31257-1. View

17.

Miles D, Gligorov J, Andre F, Cameron D, Schneeweiss A, Barrios C . Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021; 32(8):994-1004. DOI: 10.1016/j.annonc.2021.05.801. View

18.

Topper M, Vaz M, Marrone K, Brahmer J, Baylin S . The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2019; 17(2):75-90. PMC: 7254932. DOI: 10.1038/s41571-019-0266-5. View

19.

Henning A, Roychoudhuri R, Restifo N . Epigenetic control of CD8 T cell differentiation. Nat Rev Immunol. 2018; 18(5):340-356. PMC: 6327307. DOI: 10.1038/nri.2017.146. View

20.

Nishiyama A, Nakanishi M . Navigating the DNA methylation landscape of cancer. Trends Genet. 2021; 37(11):1012-1027. DOI: 10.1016/j.tig.2021.05.002. View